Aspirin and primary prevention of colorectal cancer: a still evolving story
Ce dossier contient 2 études sur la chimioprévention du cancer colorectal par l'utilisation d'aspirine : l'une se concentre sur le moment et la durée d'utilisation et l'autre analyse son association avec la survie spécifique de la maladie
Two studies reported in this issue of the Journal have provided new information on the relationship between regular aspirin use and colorectal cancer. Zhang and colleagues have addressed the use of aspirin for the primary prevention of this malignancy and have explored what dose of aspirin is required and how long it needs to be taken to reduce colorectal cancer incidence. Figueiredo and colleagues have studied whether the use of aspirin prior to or after a diagnosis of colorectal cancer affects subsequent cancer-related mortality. In both studies the authors acknowledge that their analyses are derived from observational data but are quite consistent with a large body of information about chemopreventive actions of this drug.